Skip to main content
Acta Crystallographica Section F: Structural Biology Communications logoLink to Acta Crystallographica Section F: Structural Biology Communications
. 2020 Feb 5;76(Pt 2):81–85. doi: 10.1107/S2053230X20001181

An unexpected co-crystal structure of the calpain PEF(S) domain with Hfq reveals a potential chaperone function of Hfq

Joel Cresser-Brown a, Pierre Rizkallah a, Yi Jin a, Christian Roth b, David J Miller a, Rudolf K Allemann a,*
PMCID: PMC7010360  PMID: 32039889

A co-crystal structure of the calpain PEF(S) domain bound to the Escherichia coli chaperone Hfq provides insight into the pitfalls of expression of the full-length heterodimeric calpain I complex.

Keywords: calpain expression, Hfq, chaperones, cysteine protease

Abstract

Calpain is a Ca2+-activated, heterodimeric cysteine protease consisting of a large catalytic subunit and a small regulatory subunit. Dysregulation of this enzyme is involved in a range of pathological conditions such as cancer, Alzheimer’s disease and rheumatoid arthritis, and thus calpain I is a drug target with potential therapeutic applications. Difficulty in the production of this enzyme has hindered structural and functional investigations in the past, although heterodimeric calpain I can be generated by Escherichia coli expression in low yield. Here, an unexpected structure discovered during crystallization trials of heterodimeric calpain I (CAPN1C115S + CAPNS1ΔGR) is reported. A novel co-crystal structure of the PEF(S) domain from the dissociated regulatory small subunit of calpain I and the RNA-binding chaperone Hfq, which was likely to be overproduced as a stress response to the recombinant expression conditions, was obtained, providing unexpected insight in the chaperone function of Hfq.

1. Introduction  

Proteases are ubiquitous in cellular processes that respond to a range of stimuli and signalling molecules. Calpains are a family of calcium-activated cysteine proteases consisting of 15 known isoforms in the human body. They respond to intracellular increases in Ca2+ by the specific and regulated cleav­age of a variety of targets involved in signalling pathways such as apoptosis (Wang et al., 2016), chemotaxis (Hallett & Dewitt, 2007) and cell motility (Santella et al., 1998; Miller et al., 2013). The two most studied isoforms, calpain I and calpain II, are heterodimeric proteins consisting of a large subunit (80 kDa) and a regulatory subunit (CAPNS1; 30 kDa). The large subunit contains the active site (the CysPc domain), a calcium-binding penta-EF-hand domain [PEF(L)], a calpain-type β-sandwich domain (CBSW) and an N-terminal anchor α-helix (Ono et al., 2016). The regulatory subunit CAPNS1 (30 kDa) comprises two domains: a glycine-rich domain (GR) and another calcium-binding penta-EF-hand domain [PEF(S)] (Adams et al., 2015). Calpain I and calpain II are activated in vitro by calcium concentrations of 50 and 350 µM, respectively. The large subunits of calpain I and calpain II share 62% sequence identity, while the small subunits of the two proteins are identical (Goll et al., 2003; Hitomi et al., 1998).

Calpain I and calpain II have been targeted to treat various conditions including rheumatoid arthritis, ischemic cell death and cancer (Miller et al., 2013; Bartus et al., 1995; Yamashima, 2004; Luo et al., 2015). The precise involvement of the individual enzyme isoforms in these processes remains unclear. Structural insights from crystallographic data on the heterodimeric calpain I complex could accelerate the development of therapeutics. This has been hindered by a lack of available material owing to low-yielding recombinant expression as well as challenging protein properties such as subunit dissociation, aggregation and autolysis (Hata et al., 2012; Pal et al., 2001). To tackle such difficult-to-express proteins, Escherichia coli strain C41 was developed, which is particularly well suited to the expression of toxic and membrane proteins.

Here, we present our results on the expression, purification and structure determination of human calpain I, which led to an unusual structure of the PEF(S) domain from the regulatory subunit of calpain bound to the RNA chaperone Hfq.

2. Materials and methods  

2.1. Protein purification  

E. coli C41 (DE3) pLysS cells containing the CAPN1C115S (80 kDa) and CAPNS1ΔGR (20 kDa; CAPNS1 with a truncated GR domain; Hata et al., 2013) genes were grown at 37°C in kanamycin- and ampicillin-selective TB(Enhanced) medium until the OD600 reached 0.9. Subsequently, protein production was induced with 1 mM IPTG. The protein was expressed overnight at 20°C and the cells were harvested by centrifugation in a Sorvall RC6 Plus centrifuge (Thermo Fisher Scientific, Massachusetts, USA) using an SLA-3000 rotor at 6080g for 20 min at 4°C. The cells were resuspended in 20 mM HEPES, 0.5 mM EGTA, 0.5 mM TCEP pH 7.6 (buffer A) and lysed by sonication for 5 min (pulsed; 5 s on, 10 s off). The lysate was clarified by centrifugation at 4°C for 40 min at 30 310g in a Sorvall RC6 Plus centrifuge. The supernatant was passed through a 0.2 µm syringe filter and applied onto an Ni–NTA column. The unbound protein was washed out with 15 column volumes (CV) of buffer A and the target protein was eluted with 10 CV buffer A supplemented with 250 mM imidazole. The eluted fraction containing the target protein was then applied onto a Mono Q HR 10/10 column (GE Healthcare) pre-equilibrated with buffer A. The protein was eluted with a linear gradient of 0–0.5 M NaCl in buffer A over 7 CV. The purity of the peak fractions was assessed by SDS–PAGE (10%). The solution containing the protein complex was concentrated to 10 mg ml−1 using a 30 kDa molecular-weight cutoff Vivaspin concentrator. Macromolecule-production information is summarized in Table 1.

Table 1. Macromolecule-production information.

The expression host and vectors used for PEF(S)–Hfq protein production.

Source organism Homo sapiens
DNA source CAPN1C115S (His6 tag)/CAPNS1ΔGR
Expression vector pET24(+)/pACpET24
Expression host E. coli C41 (DE3) pLysS

2.2. Crystallization  

Crystals of PEF(S)–Hfq were grown at 20°C in sitting-drop vapour-diffusion plates containing equal volumes of precipitant [0.1 M MMT (malic acid, MES and Tris in a 1:2:2 molar ratio), 25%(v/v) PEG 1500 pH 9.0] and the CAPN1C115S–CAPNS1ΔGR protein solution. Crystals were observed after 2–3 weeks. The crystals were cryoprotected with 10% ethylene glycol before being flash-cooled in liquid nitrogen and stored until data collection. Crystallization information is summarized in Table 2.

Table 2. Crystallization.

Conditions used for PEF(S)–Hfq crystallization trials.

Method Vapour diffusion
Plate type Sitting drop
Temperature (K) 293
Protein concentration (mg ml−1) 10 
Buffer composition of protein solution 20 mM HEPES, 0.5 mM EGTA, 0.5 mM TCEP pH 7.6
Composition of reservoir solution 0.1 M MMT, 25% PEG 1500 pH 9.0
Volume and ratio of drop 200 nl, 1:1
Volume of reservoir (µl) 50 

2.3. Data collection and refinement  

The resulting crystals were cubic, belonging to space group P213 (unit-cell parameters a = b = c = 147.61 Å), and diffracted to a higher resolution limit ranging from 2.9 to 2.3 Å. The structure was determined by molecular replacement using Phaser (McCoy et al., 2007) and MOLREP (Vagin & Teplyakov, 2010) as implemented within the CCP4i2 framework (Potterton et al., 2018). PDB entry 1df0 (Hosfield et al., 1999) was used as a starting model. Only domain VI, PEF(S), could be placed by MR. All attempts to place the second subunit led to stalled or increased R values during molecular replacement and subsequent refinement. The partial model was refined using alternating rounds of reciprocal refinement with REFMAC5 (Murshudov et al., 1997, 2011) and real-space refinement in Coot (Emsley et al., 2010). A polyalanine model from short stretches of ideal β-strand segments was built in the remaining unexplained electron density, subsequently refined and rebuilt to achieve a near-complete model. A combination of partial sequence information based on interpreted side-chain density, as well as fold comparison using the DALI server (Holm & Sander, 1995), pointed to Hfq as the most likely second domain in the obtained crystal structure. This was confirmed by the successful model building and refinement of the partial model with Buccaneer (Cowtan, 2006) and REFMAC5 using the correct sequence as input. Further rounds of graphical adjustment of the model using Coot, and refinement with REFMAC5, led to the final model. Other data analysis was completed with programs in the CCP4 package. The electron-density map revealed that the asymmetric unit contained four copies of the PEF(S) domain and four copies of the Hfq chaperone protein, which were noncovalently bound, and the structure was refined to R work and R free values of 0.201 and 0.247, respectively. Data-collection and processing statistics are summarized in Table 3 and refinement statistics are summarized in Table 4.

Table 3. Data collection and processing.

Data-collection and processing statistics for the PEF(S)–Hfq data set are presented. Values in parentheses are for the outer shell.

Diffraction source I04, Diamond Light Source
Wavelength (Å) 0.9795
Temperature (K) 100
Detector PILATUS3 6M, Dectris
Space group P213
a, b, c (Å) 147.607, 147.607, 147.607
α, β, γ (°) 90.0, 90.0, 90.0
Resolution range (Å) 2.32–66.02
Total No. of reflections 1029720 (75756)
No. of unique reflections 46565 (3416)
Completeness (%) 100.0 (100.0)
I/σ(I)〉 19.2 (3.0)
R r.i.m. (%) 11.6 (114.1)
Overall B factor from Wilson plot (Å2) 42.6

Table 4. Structure solution and refinement.

Refinement statistics for the PEF(S)–Hfq model deposited in the PDB as entry 6qlb.

Resolution range (Å) 2.32
No. of reflections, working set 43741
No. of reflections, test set 2337
Final R cryst 0.201
Final R free 0.247
No. of non-H atoms 7869
R.m.s. deviations
 Bond lengths (Å) 0.013
 Angles (°) 1.855
Average B factor (Å2) 51.2
Ramachandran plot
 Most favoured (%) 97.2
 Allowed (%) 2.9

3. Results and discussion  

Crystallization trials using the PACT-premier and JCSG-plus screens (Molecular Dimensions) produced several hits. The data set presented here corresponds to a P213 unit cell that is large enough to accommodate the heterodimeric calpain I structure when compared with the previously published calpain II structure (Strobl et al., 2000). After initial molecular replacement and refinement using various domains from the previously reported μ-like calpain (PDB entry 1qxp (Pal et al., 2003) and calpain II structures (PDB entry 1df0), only the PEF(S) domain could be fitted, resulting in models with poor R work and R free values and suggesting an incomplete solution. Manual model building, guided only by the difference electron density, led to a partial model for the remaining unexplained density, which could be identified as the E. coli chaperone Hfq. The structure determined from the highest resolution data set is shown in Fig. 1. The impurity (Hfq) was likely to have been overlooked in SDS gels as a small, faint band which was poorly resolved in the 10% acrylamide gels that were used (Fig. 2). It has been observed that the calpain I heterodimer can readily undergo subunit dissociation under mild conditions (Pal et al., 2001), and the stability of a PEF(S) homodimer in solution and the tendency for the large subunit to precipitate are likely to have contributed to the formation of the PEF(S)–Hfq structure. Indeed, significant precipitation was observed in many wells during the crystallization trials, including under the conditions from which crystals were harvested.

Figure 1.

Figure 1

Asymmetric unit of the calpain PEF(S)–Hfq chaperone model in cartoon representation [PEF(S), green and red; Hfq, cyan and magenta].

Figure 2.

Figure 2

SDS–PAGE (10%, reducing conditions) of Mono Q HR 10/10 purification (GE Healthcare) of CAPN1C115S + CAPNS1ΔGR, 0–0.5 M NaCl gradient over 7 CV (lane M, molecular-weight markers labelled in kDa; lanes A4–A17, peak fractions).

Although Hfq is a described contaminant that has been found to crystallize fortuitously instead of the target protein, a complex of parts of calpain I with Hfq has not been described previously. Hfq is part of the Sm-like family of proteins and is a toroid-shaped, highly conserved, homohexameric protein (Fortas et al., 2015; Brennan & Link, 2007; Schulz & Barabas, 2014). Each 8–11 kDa subunit (depending on the host organism) comprises five coiled antiparallel β-strands and an N-terminal α-helix with an unstructured C-terminus. The expression levels of Hfq depend on the cellular growth rate and phase, with an estimate of 5000–10 000 oligomers per cell for log-phase E. coli in M9 medium, with 80–90% primarily situated in the cytoplasm (Kajitani et al., 1994).

The Hfq–PEF(S) interactions show a 1:1 stoichiometry, and are primarily hydrophilic between the fourth EF-hand in the PEF(S) monomer and the Hfq nucleotide-binding site. Applying crystallographic symmetry, the classic homohexameric toroidal structure of Hfq can be observed and is highly similar to the Hfq conformation observed in Hfq alone (Schulz & Barabas, 2014; Fig. 3). The homodimeric PEF(S) surrounds the homohexamer of Hfq. The homodimeric PEF(S) structure is also highly analogous to previously observed PEF(S) complexes, suggesting little disruption of either homodimeric structure upon formation of the heterodimeric complex (Adams et al., 2014). Hydrogen bonding from the backbone O atom of Gly153 in PEF(S) to the amino group of Gln52 in Hfq at a distance of 2.95 Å is observed in the complex. The interface areas between the PEF(S) dimer pairs (chains AB and CD) are 2093 and 2017 Å2. The Hfq dimer pairs (chains EF and GH) share interface areas of between 668 and 717 Å2 (Krissinel, 2015). The mixed PEF(S)–Hfq interface areas are smaller than each homodimer interface, at between 444 and 506 Å2. The interface between PEF(S) and Hfq forms on the proximal face of the Hfq hexamer, which is reported to be the sRNA-binding site and has been shown to form a similar interface in an Hfq–catalase HPII complex (Yonekura et al., 2013). Hfq has been reported to bind at least 20 proteins such as RNAse E, which are mostly involved in genetic processes, although the functional significance of these interactions remains unclear (Butland et al., 2005).

Figure 3.

Figure 3

(a) Hfq–PEF(S) hexamer formed by crystallographic symmetry, with Hfq in cyan and magenta, and PEF(S) in green and red. (b) Hfq monomer from the Hfq–PEF(S) complex (cyan) aligned with an Hfq monomer from the native hexamer (orange; r.m.s.d. = 0.378 Å; Schulz & Barabas, 2014). (c) PEF(S) monomer from the Hfq–PEF(S) complex (red) aligned with the PEF(S) monomer from the homodimeric structure (yellow; Adams et al., 2014).

Additional density for a small molecule was found in a hydrophobic pocket in the nucleotide-binding site of all Hfq monomers, making an aromatic stacking interaction with Tyr25 (Fig. 3). The pocket is lined with leucines and iso­leucines, further increasing the hydrophobicity of the pocket. The pocket is well known to accommodate nucleotides as ligands in Hfq. The ligand was modelled as guanine, giving the best fit to the electron density (Fig. 4). Additional density for the ribose or phosphate groups of a nucleoside or nucleotide could not be traced. Although guanine had not previously been described as a ligand for this pocket, it is not unreasonable to speculate that Hfq is rather indiscriminate towards the base, given its function as an RNA chaperone.

Figure 4.

Figure 4

Guanine bound in the hydrophobic pocket between Hfq (cyan) and PEF(S) (orange). Chain residues were selected within 4 Å of the guanine ligand and Ca2+ ion (green sphere), and the map is contoured at 1.0σ.

We wondered whether Hfq might be involved as a chaperone to keep PEF(S) in solution while the large subunit PEF(L) is folded to be ready to form a complex with PEF(S). Indeed, the strength of the interaction between PEF(S) and PEF(L) (ΔG = −27.2 kJ mol−1) estimated using PISA (Krissinel, 2010) was found to be higher than that between PEF(S) and Hfq (ΔG = −12.6 kJ mol−1). Thus, the PEF(S)–Hfq oligomer may be an appropriate description of how PEF(S) is retained separately from the rest of the heterodimeric calpain I until the counterpart PEF(L), or domain IV, is ready to displace the chaperone and latch onto its PEF(S) and complete the folding during expression in this E. coli strain.

While this structure was not the original goal of these crystallographic experiments, it does provide insight into the stress that the overexpression of proteins can have on the host bacteria, and the subsequent response to these processes. The primary focus of studies of Hfq has been on its RNA-binding capabilities. It has been shown to be involved in distinct metabolic pathways, including sugar transport, membrane remodelling and quorum sensing (Brennan & Link, 2007; Fortas et al., 2015). Hfq protein–protein inter­actions have been studied to a lesser extent, not accounting for a chaperone function as a result of cellular stress. The structure presented here suggests that Hfq could play a greater role in the cellular stress response via protein-binding interactions than was previously thought (Schulz & Barabas, 2014).

Supplementary Material

PDB reference: co-crystal structure of the calpain PEF(S) domain and the E. coli Hfq chaperone, 6qlb

Acknowledgments

The CAPN1C115S and CAPNS1ΔGR plasmids were a gift from Dr Sorimachi Hiro of the Tokyo Metropolitan Institute of Medical Science, Japan. The authors also acknowledge Diamond Light Source for beamtime (proposal mx14843), and the staff of beamlines I02, I03 and I24 for assistance with crystal testing and data collection. The data set used was collected on beamline I04.

Funding Statement

This work was funded by Engineering and Physical Sciences Research Council grants EP/L504749/1 and EP/M50631X/1. Max-Planck-Gesellschaft grant .

References

  1. Adams, S. E., Rizkallah, P. J., Miller, D. J., Robinson, E. J., Hallett, M. B. & Allemann, R. K. (2014). J. Struct. Biol. 187, 236–241. [DOI] [PubMed]
  2. Adams, S. E., Robinson, E. J., Miller, D. J., Rizkallah, P. J., Hallett, M. B. & Allemann, R. K. (2015). Chem. Sci. 6, 6865–6871. [DOI] [PMC free article] [PubMed]
  3. Bartus, R. T., Elliott, P. J., Hayward, N. J., Dean, R. L., Harbeson, S., Straub, J. A., Li, Z. & Powers, J. C. (1995). Neurol. Res. 17, 249–258. [DOI] [PubMed]
  4. Brennan, R. G. & Link, T. M. (2007). Curr. Opin. Microbiol. 10, 125–133. [DOI] [PubMed]
  5. Butland, G., Peregrín-Alvarez, J. M., Li, J., Yang, W., Yang, X., Canadien, V., Starostine, A., Richards, D., Beattie, B., Krogan, N., Davey, M., Parkinson, J., Greenblatt, J. & Emili, A. (2005). Nature, 433, 531–537. [DOI] [PubMed]
  6. Cowtan, K. (2006). Acta Cryst. D62, 1002–1011. [DOI] [PubMed]
  7. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. [DOI] [PMC free article] [PubMed]
  8. Fortas, E., Piccirilli, F., Malabirade, A., Militello, V., Trépout, S., Marco, S., Taghbalout, A. & Arluison, V. (2015). Biosci. Rep. 35, 1–9. [DOI] [PMC free article] [PubMed]
  9. Goll, D. E., Thompson, V. F., Li, H., Wei, W. & Cong, J. (2003). Physiol Rev. 83, 731–801. [DOI] [PubMed]
  10. Hallett, M. B. & Dewitt, S. (2007). Trends Cell Biol. 17, 209–214. [DOI] [PubMed]
  11. Hata, S., Kitamura, F. & Sorimachi, H. (2013). Genes Cells, 18, 753–763. [DOI] [PubMed]
  12. Hata, S., Ueno, M., Kitamura, F. & Sorimachi, H. (2012). J. Biochem. 151, 417–422. [DOI] [PubMed]
  13. Hitomi, K., Uchiyama, Y., Ohkubo, I., Kunimatsu, M., Sasaki, M. & Maki, M. (1998). Biochem. Biophys. Res. Commun. 246, 681–685. [DOI] [PubMed]
  14. Holm, L. & Sander, C. (1995). Trends Biochem. Sci. 20, 478–480. [DOI] [PubMed]
  15. Hosfield, C. M., Elce, J. S., Davies, P. L. & Jia, Z. (1999). EMBO J. 18, 6880–6889. [DOI] [PMC free article] [PubMed]
  16. Kajitani, M., Kato, A., Wada, A., Inokuchi, Y. & Ishihama, A. (1994). J. Bacteriol. 176, 531–534. [DOI] [PMC free article] [PubMed]
  17. Krissinel, E. (2010). J. Comput. Chem. 31, 133–143. [DOI] [PubMed]
  18. Krissinel, E. (2015). Nucleic Acids Res. 43, W314–W319. [DOI] [PMC free article] [PubMed]
  19. Luo, T., Yue, R., Hu, H., Zhou, Z., Yiu, K. H., Zhang, S., Xu, L., Li, K. & Yu, Z. (2015). Arch. Biochem. Biophys. 586, 1–9. [DOI] [PubMed]
  20. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. [DOI] [PMC free article] [PubMed]
  21. Miller, D. J., Adams, S. E., Hallett, M. B. & Allemann, R. K. (2013). Future Med. Chem. 5, 2057–2074. [DOI] [PubMed]
  22. Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. [DOI] [PMC free article] [PubMed]
  23. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Acta Cryst. D53, 240–255. [DOI] [PubMed]
  24. Ono, Y., Saido, T. C. & Sorimachi, H. (2016). Nat. Rev. Drug Discov. 15, 854–876. [DOI] [PubMed]
  25. Pal, G. P., Elce, J. S. & Jia, Z. (2001). J. Biol. Chem. 276, 47233–47238. [DOI] [PubMed]
  26. Pal, G. P., Veyra, T. D., Elce, J. S. & Jia, Z. (2003). Structure, 11, 1521–1526. [DOI] [PubMed]
  27. Potterton, L., Agirre, J., Ballard, C., Cowtan, K., Dodson, E., Evans, P. R., Jenkins, H. T., Keegan, R., Krissinel, E., Stevenson, K., Lebedev, A., McNicholas, S. J., Nicholls, R. A., Noble, M., Pannu, N. S., Roth, C., Sheldrick, G., Skubak, P., Turkenburg, J., Uski, V., von Delft, F., Waterman, D., Wilson, K., Winn, M. & Wojdyr, M. (2018). Acta Cryst. D74, 68–84. [DOI] [PMC free article] [PubMed]
  28. Santella, L., Kyozuka, K., De Riso, L. & Carafoli, E. (1998). Cell Calcium, 23, 123–130. [DOI] [PubMed]
  29. Schulz, E. C. & Barabas, O. (2014). Acta Cryst. F70, 1492–1497. [DOI] [PMC free article] [PubMed]
  30. Strobl, S., Fernandez-Catalan, C., Braun, M., Huber, R., Masumoto, H., Nakagawa, K., Irie, A., Sorimachi, H., Bourenkow, G., Bartunik, H., Suzuki, K. & Bode, W. (2000). Proc. Natl Acad. Sci. USA, 97, 588–592. [DOI] [PMC free article] [PubMed]
  31. Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25. [DOI] [PubMed]
  32. Wang, C., Shi, D., Song, X., Chen, Y., Wang, L. & Zhang, X. (2016). Neurochem. Int. 97, 15–25. [DOI] [PubMed]
  33. Yamashima, T. (2004). Cell Calcium, 36, 285–293. [DOI] [PubMed]
  34. Yonekura, K., Watanabe, M., Kageyama, Y., Hirata, K., Yamamoto, M. & Maki-Yonekura, S. (2013). PLoS One, 8, e78216. [DOI] [PMC free article] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

PDB reference: co-crystal structure of the calpain PEF(S) domain and the E. coli Hfq chaperone, 6qlb


Articles from Acta Crystallographica. Section F, Structural Biology Communications are provided here courtesy of International Union of Crystallography

RESOURCES